{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Treatment+Phase+2", "query": { "intervention": "Treatment Phase 2" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 25248, "total_pages": 2525, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Treatment+Phase+2&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-11T19:53:33.272Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00009906", "title": "Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastrointestinal Stromal Tumor" ], "interventions": [ { "name": "Imatinib Mesylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 748, "start_date": "2000-12", "completion_date": "2014-11", "has_results": false, "last_update_posted_date": "2014-12-23", "last_synced_at": "2026-09-11T19:53:33.272Z", "location_count": 132, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 99 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00009906" }, { "nct_id": "NCT01747915", "title": "A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Generalized Tonic Clonic Seizures" ], "interventions": [ { "name": "Pregabalin Dose Level 1", "type": "DRUG" }, { "name": "Pregabalin Dose Level 2", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "5 Years to 65 Years" }, "enrollment_count": 219, "start_date": "2013-04-03", "completion_date": "2019-02-20", "has_results": true, "last_update_posted_date": "2021-01-20", "last_synced_at": "2026-09-11T19:53:33.272Z", "location_count": 12, "location_summary": "Loxahatchee Groves, Florida • Orlando, Florida • Port Charlotte, Florida + 6 more", "locations": [ { "city": "Loxahatchee Groves", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Port Charlotte", "state": "Florida" }, { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT01747915" }, { "nct_id": "NCT00287235", "title": "Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hepatic Encephalopathy", "Liver Failure", "Hepatitis, Chronic", "Liver Cirrhosis" ], "interventions": [ { "name": "MARS", "type": "DEVICE" }, { "name": "Standard Medical Therapy", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Vantive Health LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2000-09", "completion_date": "2004-04", "has_results": false, "last_update_posted_date": "2025-03-03", "last_synced_at": "2026-09-11T19:53:33.272Z", "location_count": 6, "location_summary": "Birmingham, Alabama • San Diego, California • Chicago, Illinois + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00287235" }, { "nct_id": "NCT00002225", "title": "A Study of Efavirenz in Combination With Stavudine and Didanosine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Efavirenz", "type": "DRUG" }, { "name": "Stavudine", "type": "DRUG" }, { "name": "Didanosine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dupont Merck", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 60, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-09-11T19:53:33.272Z", "location_count": 5, "location_summary": "Washington D.C., District of Columbia • Chicago, Illinois • Manhassett, New York + 2 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Manhassett", "state": "New York" }, { "city": "Rochester", "state": "New York" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002225" }, { "nct_id": "NCT05123040", "title": "Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute-graft-versus-host Disease" ], "interventions": [ { "name": "Ruxolitinib 10 MG Oral Tablet", "type": "DRUG" }, { "name": "hCG", "type": "DRUG" }, { "name": "Corticosteroids", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 10, "start_date": "2023-06-05", "completion_date": "2026-02-27", "has_results": false, "last_update_posted_date": "2026-03-24", "last_synced_at": "2026-09-11T19:53:33.272Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05123040" }, { "nct_id": "NCT01967940", "title": "Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV", "HIV Infections", "Acquired Immunodeficiency Syndrome" ], "interventions": [ { "name": "TAF", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "E/C/F/TAF", "type": "DRUG" }, { "name": "Current failing ARV regimen", "type": "DRUG" }, { "name": "ATV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2013-10-25", "completion_date": "2017-07-31", "has_results": true, "last_update_posted_date": "2018-11-16", "last_synced_at": "2026-09-11T19:53:33.272Z", "location_count": 5, "location_summary": "Ft. Pierce, Florida • West Palm Beach, Florida • Wilton Manors, Florida + 2 more", "locations": [ { "city": "Ft. Pierce", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Wilton Manors", "state": "Florida" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01967940" }, { "nct_id": "NCT02549989", "title": "Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Cancer", "Recurrent Endometrial Cancer" ], "interventions": [ { "name": "LY3023414", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 28, "start_date": "2015-09", "completion_date": "2022-03-23", "has_results": true, "last_update_posted_date": "2023-02-22", "last_synced_at": "2026-09-11T19:53:33.272Z", "location_count": 6, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02549989" }, { "nct_id": "NCT00345189", "title": "Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tumors", "Lymphoma" ], "interventions": [ { "name": "CNF2024", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2006-02", "completion_date": "2009-04", "has_results": false, "last_update_posted_date": "2009-07-14", "last_synced_at": "2026-09-11T19:53:33.272Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • New Haven, Connecticut • San Antonio, Texas", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00345189" }, { "nct_id": "NCT01605318", "title": "Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer", "Colon Cancer", "Rectal Cancer" ], "interventions": [ { "name": "Labetuzumab Govitecan (LG)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 92, "start_date": "2013-02-12", "completion_date": "2017-01-03", "has_results": false, "last_update_posted_date": "2024-01-24", "last_synced_at": "2026-09-11T19:53:33.272Z", "location_count": 7, "location_summary": "Santa Monica, California • Aurora, Colorado • Newark, Delaware + 4 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Newark", "state": "Delaware" }, { "city": "Goshen", "state": "Indiana" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01605318" }, { "nct_id": "NCT01997190", "title": "Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Pleural Effusion", "Lung Cancer", "Mesothelioma", "Breast Cancer", "Ovarian Cancer" ], "interventions": [ { "name": "AdV-tk + valacyclovir", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Candel Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2013-10", "completion_date": "2018-02", "has_results": false, "last_update_posted_date": "2023-08-25", "last_synced_at": "2026-09-11T19:53:33.272Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01997190" } ] }